22744-13-4

Basic information

• Product Name: {2-[4-(methoxycarbonyl)phenyl]-2-oxoethylidene}diazenium
• CAS NO: 22744-13-4
• Molecular Formula: C₁₀H₈N₂O₃
• Molecular Weight: 205.1895
• Mol File: 22744-13-4.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: {2-[4-(methoxycarbonyl)phenyl]-2-oxoethylidene}diazenium(CAS DataBase Reference)
• NIST Chemistry Reference: {2-[4-(methoxycarbonyl)phenyl]-2-oxoethylidene}diazenium(22744-13-4)
• EPA Substance Registry System: {2-[4-(methoxycarbonyl)phenyl]-2-oxoethylidene}diazenium(22744-13-4)

Safety Data

• Hazardous Substances Data: 22744-13-4(Hazardous Substances Data)

Usage

Description

2-[4-(methoxycarbonyl)phenyl]-2-oxoethylidenediazenium is a chemical compound belonging to the diazeniumdiolate family. It functions as a nitric oxide donor, releasing nitric oxide upon decomposition in aqueous solutions. 2-[4-(methoxycarbonyl)phenyl]-2-oxoethylidenediazenium holds potential therapeutic applications due to nitric oxide's involvement in various physiological processes such as smooth muscle relaxation, vasodilation, and neurotransmission. The presence of a carbonyl group in the compound enables a controlled release of nitric oxide, making it a promising candidate for drug development in the treatment of cardiovascular diseases, pulmonary hypertension, and other conditions related to nitric oxide deficiency. However, further research is necessary to fully comprehend the potential benefits and limitations of this compound.

Uses

Used in Pharmaceutical Applications:
2-[4-(methoxycarbonyl)phenyl]-2-oxoethylidenediazenium is used as a therapeutic agent for the treatment of cardiovascular diseases, pulmonary hypertension, and other conditions related to nitric oxide deficiency. 2-[4-(methoxycarbonyl)phenyl]-2-oxoethylidenediazenium's ability to release nitric oxide in a controlled manner aids in addressing these health issues.
Used in Drug Development:
In the pharmaceutical industry, 2-[4-(methoxycarbonyl)phenyl]-2-oxoethylidenediazenium is used as a key compound in the development of new drugs targeting conditions associated with nitric oxide deficiency. Its controlled release of nitric oxide makes it a valuable asset in creating effective treatments for various medical conditions.
Used in Research and Development:
2-[4-(methoxycarbonyl)phenyl]-2-oxoethylidenediazenium is utilized as a research compound to further understand the role of nitric oxide in physiological processes and its potential applications in medicine. This knowledge can contribute to the development of novel therapeutic strategies and treatments for a range of health conditions.

Upstream product

• 186581-53-3 diazomethane 
• 7377-26-6 4-Methoxycarbonylbenzoyl chloride 
• 3609-53-8 methyl 4-acetylbenzoate 
• 1679-64-7 Monomethyl terephthalate 
• 120-61-6 1,4-benzenedicarboxylic acid dimethyl ester 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 22744-12-3 [4-(methoxycarbonyl)phenyl]acetic acid 
• 52540-22-4 methyl 4-(2-chloroacetyl)benzoate 
• 125569-73-5 2-cyclohexyl-7-(methoxycarbonyl)-3-(triisopropylsiloxy)-1-naphthol 
• 160196-18-9 1-<(4-Methoxycarbonyl)phenyl>-1,6-dioxo-dodeca-2,4-(E,E)-diene 
• 433935-24-1 methyl 4-(2-{2-[2-(2-methoxyethoxy)ethoxy]ethoxy}acetyl)benzoate 
• 448922-67-6 methyl 4-(2'-diazo-2'-triisopropylsilylacetyl) benzoate 
• 916080-53-0 methyl 4-(3-chloro-2-oxopropyl)benzoate 
• 916080-54-1 methyl 4-[(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl]benzoate 
• 916080-55-2 methyl 4-[(2,4-diaminofuro[2,3-d]pyrimidin-5-yl)methyl]benzoate 
• 916080-56-3 4-[(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl]benzoic acid 
• 916080-57-4 4-[(2,4-diaminofuro[2,3-d]pyrimidin-5-yl)methyl]benzoic acid 
• 916080-58-5 diethyl N-{4-[(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl]benzoyl}-L-glutamate 
• 916080-59-6 diethyl N-{4-[(2,4-diaminofuro[2,3-d]pyrimidin-5-yl)methyl]benzoyl}-L-glutamate 
• 518063-75-7 C₁₉H₁₉N₅O₆ 

Relevant articles and documents

ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model

Lysophosphatidic acid (LPA) is a bioactive lipid mediator that elicits a number of biological functions, including smooth muscle contraction, cell motility, proliferation, and morphological change. LPA is endogenously produced by autotaxin (ATX) from extracellular lysophosphatidylcholine (LPC) in plasma. Herein, we report our medicinal chemistry effort to identify a novel and highly potent ATX inhibitor, ONO-8430506 (20), with good oral availability. To enhance the enzymatic ATX inhibitory activity, we designed several compounds by structurally comparing our hit compound with the endogenous ligand LPC. Further optimization to improve the pharmacokinetic profile and enhance the ATX inhibitory activity in human plasma resulted in the identification of ONO-8430506 (20), which enhanced the antitumor effect of paclitaxel in a breast cancer model.

Synthesis and evaluation of a classical 2,4-diamino-5-substituted-furo[2,3-d]pyrimidine and a 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidine as antifolates

Two classical antifolates, a 2,4-diamino-5-substituted furo[2,3-d]pyrimidine and a 2-amino-4-oxo-6-substituted pyrrolo[2,3-d]pyrimidine, were synthesized as potential inhibitors of dihydrofolate reductase (DHFR) and thymidylate synthase (TS). The synthese

[60]Fullerene as a substituent

The substituent effect of the dihydro[60]fullerenyl group and its hydrophobic parameters have been evaluated quantitatively. The substituent constant has been determined from the pK value of a fullerene-based, para-substituted benzoic acid 1 in 80% dioxan